Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;16(1):121-32.
doi: 10.1634/theoncologist.2010-0183. Epub 2011 Jan 6.

Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw

Rebecca Anne Miksad  1 , Kuan-Chi Lai, Thomas Benton Dodson, Sook-Bin Woo, Nathaniel Simon Treister, Omosalewa Akinyemi, Marian Bihrle, Guy Maytal, Meredith August, G Scott Gazelle, J Shannon Swan
Affiliations

Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw

Rebecca Anne Miksad et al. Oncologist. 2011.

Abstract

Purpose: Potentially debilitating, osteonecrosis of the jaw (ONJ) is an emerging complication of bisphosphonates. However, its effect on quality of life (QoL) is unknown. We determined the ONJ-related QoL decline in a cancer patient cohort.

Patients and methods: Thirty-four cancer patients with bisphosphonate-associated ONJ completed a telephone survey (October 2007 through May 2008). The Oral Health Impact Profile 14 (OHIP) retrospectively assessed participant oral health-related QoL before and after ONJ. Standardized ONJ descriptions were developed in a multidisciplinary, iterative process and were evaluated with three frequently used preference-based QoL measurement methods on a 0 (death) to 1 (perfect health) scale: Visual Analogue Scale (VAS), Time Trade-Off (TTO), and EQ-5D.

Results: ONJ significantly (p < .001) increased OHIP scores (worse QoL) for additive (3.56-16.53) and weighted (7.0-17.5) methods. Seven individual OHIP items significantly increased (Bonferroni correction p < .0035): pain, eating discomfort, self-consciousness, unsatisfactory diet, interrupted meals, irritability, and decreased life satisfaction. Mean preference-based QoL values significantly decreased (p < .001) with worsening ONJ stage (VAS, TTO, and EQ-5D): no ONJ (0.76, 0.86, 0.82), ONJ stage 1 (0.69, 0.82, 0.78), ONJ stage 2 (0.51, 0.67, 0.55), and ONJ stage 3 (0.37, 0.61, 0.32). As ONJ worsened, EQ-5D domain scores significantly increased (p < .001). Pain/discomfort and anxiety/depression contributed most to declining QoL.

Conclusions: ONJ significantly affects QoL, a detriment that increases with worsening ONJ. QoL impairments for ONJ stages 2 and 3 are similar to other treatment side effects that influence decision-making. Bisphosphonate-associated ONJ QoL is an important consideration for patients, clinicians, and policy makers.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Rebecca Anne Miksad: None; Kuan-Chi Lai: None; Thomas Benton Dodson: None; Sook-Bin Woo: None; Nathaniel Simon Treister: None; Omosalewa Akinyemi: None; Marian Bihrle: None; Guy Maytal: None; Meredith August: None; G. Scott Gazelle: None; J. Shannon Swan: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

Figures

Figure 1.
Figure 1.
Enrollment of patients.
Figure 2.
Figure 2.
Preference-based QoL assessment. (A): Mean (SD) utility value for ONJ health states. (B): ONJ utility decrement by stage. (C): Mean scores of EQ-5D domains (numbers listed in supplemental online Table 1). Abbreviations: ONJ, osteonecrosis of the jaw; QoL, quality of life; TTO, Time Trade-off; VAS, Visual Analogue Scale.
See this image and copyright information in PMC

References

    1. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(2):186–193. - PubMed
    1. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med. 2007;36(6):319–328. - PubMed
    1. Lam DK, Sandor GK, Holmes HI, et al. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007;73(5):417–422. - PubMed
    1. Mariotti A. Bisphosphonates and osteonecrosis of the jaws. J Dent Educ. 2008;72(8):919–929. - PubMed
    1. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7(6):508–514. - PubMed

Publication types

Substances